Skip to main
IRD

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 30%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics Inc. demonstrates a promising growth outlook due to its extensive pipeline of therapies aimed at treating inherited retinal diseases, which includes potential for significant advancements in visual acuity improvements. The company's clinical studies reveal that patients have experienced notable enhancements in vision, suggesting durable outcomes that may encourage patient uptake and market acceptance. Additionally, the growth in general and administrative expenses is indicative of ongoing investment in operational capabilities, potentially positioning the company favorably for future commercialization and revenue generation as its innovative treatments progress through development stages.

Bears say

Opus Genetics Inc. has experienced substantial financial losses since its inception, indicating challenges in achieving profitability amid ongoing operational expenses. The company faces significant market competition from emerging therapies that target similar indications, which could hinder its ability to penetrate the market effectively and secure favorable pricing for its products. Additionally, potential delays in clinical development, regulatory approvals, or commercialization processes may prolong development timelines and escalate costs, thereby posing further risks to the viability of Opus's therapeutic programs.

Opus Genetics (IRD) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Opus Genetics (IRD) has a Strong Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.